JP2005506833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506833A5 JP2005506833A5 JP2003502172A JP2003502172A JP2005506833A5 JP 2005506833 A5 JP2005506833 A5 JP 2005506833A5 JP 2003502172 A JP2003502172 A JP 2003502172A JP 2003502172 A JP2003502172 A JP 2003502172A JP 2005506833 A5 JP2005506833 A5 JP 2005506833A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- nucleic acid
- cell
- acid molecule
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 52
- 150000007523 nucleic acids Chemical class 0.000 claims 28
- 210000004027 cells Anatomy 0.000 claims 25
- 108020004707 nucleic acids Proteins 0.000 claims 24
- 239000000523 sample Substances 0.000 claims 19
- 102000004965 antibodies Human genes 0.000 claims 12
- 108090001123 antibodies Proteins 0.000 claims 12
- 230000003902 lesions Effects 0.000 claims 10
- 125000003275 alpha amino acid group Chemical class 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 7
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 230000000051 modifying Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241000238631 Hexapoda Species 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- 230000001594 aberrant Effects 0.000 claims 2
- 230000001580 bacterial Effects 0.000 claims 2
- 210000004962 mammalian cells Anatomy 0.000 claims 2
- 230000003334 potential Effects 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 230000036947 Dissociation constant Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001413 cellular Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000000295 complement Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
Claims (50)
(a)該試料を用意すること;
(b)ポリペプチドに免疫特異的に結合する抗体に該試料を導入すること;および
(c)該ポリペプチドに結合する抗体の存在または量を測定し、それにより該試料中のポリペプチドの存在または量を測定すること
を含む、方法。 A method for determining the presence or amount of a polypeptide of claim 1 in a sample, the method comprising:
(A) preparing the sample;
(B) introducing the sample into an antibody that immunospecifically binds to the polypeptide; and (c) determining the presence or amount of the antibody that binds to the polypeptide, thereby the presence of the polypeptide in the sample Or a method comprising measuring an amount.
a)第1の哺乳動物の対象由来試料中のポリペプチド発現のレベルを測定すること;および
b)ステップ(a)の試料中の該ポリペプチドの発現を、該疾患または素因を有さないことが知られている第2の哺乳動物の対象由来の対照試料中に存在するポリペプチドの発現と比較することを含み、
対照試料と比較するときの第1の対象中のポリペプチドの発現のレベルの変化は、該疾患の存在または素因を示す、方法。 A method for determining the presence or predisposition of a disease associated with an altered level of expression of a polypeptide of claim 1 in a first mammalian subject comprising:
a) measuring the level of polypeptide expression in the sample from the first mammalian subject; and b) not expressing the polypeptide in the sample of step (a) with the disease or predisposition Comparing the expression of the polypeptide present in a control sample from a known second mammalian subject,
The method wherein a change in the level of expression of the polypeptide in the first subject as compared to a control sample is indicative of the presence or predisposition of the disease.
(a)該剤に該ポリペプチドを導入すること;および
(b)該剤が該ポリペプチドに結合するか否かを測定すること、
を含む、方法。 A method of identifying an agent that binds to the polypeptide of claim 1 comprising:
(A) introducing a said polypeptide to said agent; and (b) that said agent determining whether binding to the polypeptide,
Including a method.
(a)請求項1に記載のポリペプチドを発現し、かつポリペプチドに起因する性質または機能を有する細胞を用意すること;
(b)候補物質を含む組成物と細胞を接触させること;および
(c)物質がポリペプチド起因する性質または機能を変化させるか否かを測定することを含み;
それにより、もし物質の存在下で観察される変化が、細胞を物質の非存在下で組成物と接触させたときには観察されなければ、物質は潜在的治療剤として同定される、方法。 A method of identifying a potential therapeutic agent for use in the treatment of a lesion, wherein the lesion is associated with aberrant expression or aberrant physiological interactions of the polypeptide of claim 1, the method comprising:
(A) preparing a cell that expresses the polypeptide according to claim 1 and has a property or function attributable to the polypeptide;
(B) contacting the cell with a composition comprising the candidate substance; and (c) determining whether the substance alters the property or function attributable to the polypeptide;
Thereby, if a change observed in the presence of a substance is not observed when the cell is contacted with the composition in the absence of the substance, the substance is identified as a potential therapeutic agent.
(a)請求項1に記載のポリペプチドと関連する病変のリスクが増大している被検動物に試験化合物を投与すること、但し、該被検動物は、請求項1に記載のポリペプチドを組換え的に発現している、
(b)ステップ(a)の化合物の投与後に該被検動物中の該ポリペプチドの活性を測定すること;および
(c)該被検動物中の該ポリペプチドの活性を、該ポリペプチドを投与されていない対照動物における該ポリペプチドの活性と比較すること、但し、該対照動物と比べた該被検動物における該ポリペプチドの活性の変化は、試験化合物が請求項1に記載のポリペプチドと関連する病変の活性または潜在活性のモジュレーター、または素因であることを示すこと;
を含む、当該方法。 A method of screening for a modulator or predisposition of a lesion activity or potential activity associated with a polypeptide of claim 1, comprising:
(A) administering a test compound to a test animal having an increased risk of a lesion associated with the polypeptide of claim 1, provided that the test animal receives the polypeptide of claim 1; Expressed recombinantly,
(B) measuring the activity of the polypeptide in the subject animal after administration of the compound of step (a); and (c) administering the polypeptide to determine the activity of the polypeptide in the subject animal. Comparing the activity of the polypeptide in an untreated control animal, provided that the change in the activity of the polypeptide in the test animal compared to the control animal is such that the test compound and the polypeptide of claim 1 Indicate that it is a modulator or predisposition to the activity or potential activity of the associated lesion;
Including the method.
(a)該試料を用意すること;
(b)該核酸分子に結合するプローブに該試料を導入すること;および
(c)該核酸分子に結合する該プローブの存在または量を測定することを含み、
それにより該試料中の核酸分子の存在または量を測定する、方法。 A method for measuring the presence or amount of a nucleic acid molecule according to claim 20 in a sample comprising:
(A) preparing the sample;
(B) introducing the sample into a probe that binds to the nucleic acid molecule; and (c) measuring the presence or amount of the probe that binds to the nucleic acid molecule;
A method thereby measuring the presence or amount of nucleic acid molecules in the sample.
a)第1の哺乳動物の対象由来の試料における核酸の発現レベルを測定すること;および
b)ステップ(a)の試料中の該核酸分子の発現のレベルを、疾患または素因を有さないことが知られている第2の哺乳動物の対象由来の対照試料中に存在する核酸の発現のレベルと比較すること;
を含み、
対照試料と比較するときの第1の対象における核酸分子の発現のレベルの変化は、疾患の存在または素因を示す、方法。 A method for determining the presence or predisposition of a disease associated with an altered level of expression of a nucleic acid molecule of claim 20 in a first mammalian subject comprising:
a) measuring the expression level of a nucleic acid in a sample from a first mammalian subject; and b) not having a disease or predisposition to the level of expression of the nucleic acid molecule in the sample of step (a) Comparing the level of expression of the nucleic acid present in a control sample from a second mammalian subject of known;
Including
The method wherein a change in the level of expression of the nucleic acid molecule in the first subject when compared to the control sample is indicative of the presence or predisposition of the disease.
Applications Claiming Priority (30)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29560701P | 2001-06-04 | 2001-06-04 | |
US29641801P | 2001-06-06 | 2001-06-06 | |
US29640401P | 2001-06-06 | 2001-06-06 | |
US29657501P | 2001-06-07 | 2001-06-07 | |
US29741401P | 2001-06-11 | 2001-06-11 | |
US29757301P | 2001-06-12 | 2001-06-12 | |
US29756701P | 2001-06-12 | 2001-06-12 | |
US29828501P | 2001-06-14 | 2001-06-14 | |
US29855601P | 2001-06-15 | 2001-06-15 | |
US29852801P | 2001-06-15 | 2001-06-15 | |
US29913301P | 2001-06-18 | 2001-06-18 | |
US29923001P | 2001-06-19 | 2001-06-19 | |
US29994901P | 2001-06-21 | 2001-06-21 | |
US30017701P | 2001-06-22 | 2001-06-22 | |
US30155001P | 2001-06-28 | 2001-06-28 | |
US30153001P | 2001-06-28 | 2001-06-28 | |
US30295101P | 2001-07-03 | 2001-07-03 | |
US31877101P | 2001-09-12 | 2001-09-12 | |
US32468701P | 2001-09-25 | 2001-09-25 | |
US33926601P | 2001-10-24 | 2001-10-24 | |
US33752401P | 2001-11-16 | 2001-11-16 | |
US34114301P | 2001-12-14 | 2001-12-14 | |
US35915102P | 2002-02-21 | 2002-02-21 | |
US35864302P | 2002-02-21 | 2002-02-21 | |
US36119502P | 2002-02-28 | 2002-02-28 | |
US36196402P | 2002-03-05 | 2002-03-05 | |
US37152302P | 2002-04-10 | 2002-04-10 | |
US37134602P | 2002-04-10 | 2002-04-10 | |
US10/161,493 US20040018555A1 (en) | 2001-06-04 | 2002-06-03 | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
PCT/US2002/017559 WO2002099062A2 (en) | 2001-06-04 | 2002-06-04 | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005506833A JP2005506833A (en) | 2005-03-10 |
JP2005506833A5 true JP2005506833A5 (en) | 2006-01-05 |
Family
ID=30773846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003502172A Pending JP2005506833A (en) | 2001-06-04 | 2002-06-04 | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding antigens, and methods of use |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1401470A4 (en) |
JP (1) | JP2005506833A (en) |
CA (1) | CA2447935A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009000099A2 (en) * | 2007-06-25 | 2008-12-31 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
TW201627003A (en) * | 2010-04-02 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | ECT2 peptides and vaccines including the same |
CN113604480B (en) * | 2021-09-17 | 2023-07-04 | 四川农业大学 | Corn transcription factor ZmHsf28 and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003514530A (en) * | 1999-11-19 | 2003-04-22 | キュラジェン コーポレイション | Polypeptides and nucleic acids encoding them |
WO2001083782A2 (en) * | 2000-05-04 | 2001-11-08 | Sugen, Inc. | Novel proteases |
WO2002020736A2 (en) * | 2000-09-08 | 2002-03-14 | Incyte Genomics Inc | Proteases |
AU2002222658A1 (en) * | 2000-12-18 | 2002-07-01 | Yamanouchi Pharmaceutical Co..Ltd. | Novel aggrecanase |
-
2002
- 2002-06-04 CA CA002447935A patent/CA2447935A1/en not_active Abandoned
- 2002-06-04 JP JP2003502172A patent/JP2005506833A/en active Pending
- 2002-06-04 EP EP02732027A patent/EP1401470A4/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005512515A5 (en) | ||
JP2003505075A5 (en) | ||
AU2006321906B2 (en) | Uses of myostatin antagonists | |
CA2195955A1 (en) | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof | |
CZ291047B6 (en) | Pharmaceutical composition containing antagonists of growth factor of vascular endothelial cells | |
FR2772047B1 (en) | GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION | |
CA2301173A1 (en) | Cysteine rich receptors-train | |
JP2001512667A (en) | Human orphan receptor NTR-1 | |
JP4489303B2 (en) | Method for treating hypomotility disorders of the gastrointestinal tract using neurotrophin and analogs thereof | |
KR950701379A (en) | RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR | |
JP2004500037A5 (en) | ||
CA2522994A1 (en) | Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer | |
JP2005528080A5 (en) | ||
JP3472587B2 (en) | Bone-related carboxypeptidase-like protein and method for producing the same | |
JP2004533235A5 (en) | ||
JP4654029B2 (en) | Single domain TDF related compounds and analogs thereof | |
JP2005506833A5 (en) | ||
WO2016109823A1 (en) | Treatment of pediatric growth hormone deficiency with human growth hormone analogues | |
RU97104072A (en) | BODY WEIGHT MODULATORS ACCORDING TO NUCLEIC ACIDS AND PROTEINS, AND ALSO THEIR APPLICATION FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES | |
JP5099943B2 (en) | Polypeptide, polynucleotide and use thereof | |
WO2002030974A2 (en) | Proteins and nucleic acids encoding same | |
JP2005504514A5 (en) | ||
JP2005512509A5 (en) | ||
JP2005528886A5 (en) | ||
JP2005526507A5 (en) |